Brevifoliol ester induces apoptosis in prostate cancer cells by activation of caspase pathway

Area of Science:

• Natural Product Chemistry
• Medicinal Chemistry
• Cancer Biology

Background:

• Prostate cancer is a significant global health concern, ranking as the fourth most common cancer worldwide.
• Brevifoliol, a taxoid derived from Taxus wallichiana, serves as a starting point for novel anti-cancer agent development.
• The need for effective and selective prostate cancer therapeutics drives research into novel compound synthesis and evaluation.

Purpose of the Study:

• To synthesize and evaluate novel C5 ester derivatives of brevifoliol for anti-cancer activity.
• To identify specific analogues with potent and selective cytotoxicity against prostate cancer cell lines.
• To investigate the mechanism of action, in-vivo efficacy, and safety profile of promising compounds.

Main Methods:

• Steglich esterification was employed to create diverse C5 ester analogues of brevifoliol.
• Seventeen synthesized analogues were screened for cytotoxicity against human cancer cell lines using the MTT assay.
• Cell cycle analysis, caspase-3 activation assays, and in-vivo studies (Ehrlich ascites carcinoma model) were performed.
• Acute oral toxicity studies were conducted in Swiss albino mice.

Main Results:

• Two semi-synthetic brevifoliol esters, analogues 13 and 16, demonstrated potent and selective cytotoxicity against PC-3 prostate cancer cells.
• Analogue 13 induced S and G2/M phase cell cycle arrest and apoptosis via caspase-3 activation.
• Compound 13 exhibited moderate efficacy in an in-vivo model and was found to be safe at doses up to 1,000 mg/kg.

Conclusions:

• Brevifoliol ester 13 is a promising lead compound with selective anti-prostate cancer activity and a favorable safety profile.
• Further optimization of brevifoliol ester 13 could lead to more effective therapeutic agents for prostate cancer.
• This study highlights the potential of taxoid derivatives from natural sources in cancer drug discovery.